In Brief: Ad, Social Media Claims Scrutinized; Unilever Slims Down; Perrigo Generic Advil Congestion Ready

NAD refers RDK Global advertising to FTC; social media claims trigger FDA warning; Perrigo to launch equivalent of Advil product; Unilever divests Slim-Fast; class-action complaint against Nu Skin; Herbalife makes friends on Capitol Hill; and child-proof liquid nicotine bill introduced.

Claims that RDK Global’s dietary supplement Provailen “stops arthritis pain at the source” and has “zero side effects” could imply the product is an alternative to FDA-approved medication and encourage consumers to forgo treatment, the Council for Responsible Nutrition said in a case it brought to the National Advertising Division. NAD referred the case to the Federal Trade Commission after RDK refused to participate in the review process. The Council of Better Business Bureaus division noted the Coatbridge, Scotland-based firm, which also markets weight-loss supplement brands Phen375, Adiphene, Optimus and KouTea and Brestrogen “breast enhancement cream,” should substantiate a testimonial that suggested the Reishi mushroom formula alleviated a user’s shoulder and joint pain to the point that surgery was not necessary. CRN argued the express and implied benefit claims in the testimonial must reflect typical results when the product is used as directed. The trade group brought the challenge as part of the initiative it supports to expand NAD’s review of supplement claims.

Social media claims on Twitter and Facebook that Zarbee’s Naturals products provide cold and cough relief make the products unapproved...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By 

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

More from North America

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By 

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.